Versantis is a Biotech company developing breakthrough liver disease treatments and diagnostics addressing high unmet medical needs.
Its lead candidate, VS-01, is currently at preclinical stage and has the potential to be the first treatment for acute liver disease, simultaneously supporting multiple failing organs. VS-01 targets three rare indications and received orphan drug status. In addition, Versantis’ pipeline promises to improve patients’ outcome in other medical fields; VS-02 and VS-03 are developed for chronic liver diseases and for the treatment of drug intoxications, both representing large market opportunities.
Versantis in the News: